MDWD | tickerfilter.com

Fundamental analysis

55%

Profitability 50%

Dept financing 50%

Liquidity 75%

Performance 55%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.11%

1 Month

11.10%

3 Months

-7.27%

6 Months

-9.11%

1 Year

-8.58%

2 Year

-13.01%

Key data

Stock price

$16.72

P/E Ratio

-9.93

DAY RANGE

$16.24 - $16.99

EPS

-$0.34

52 WEEK RANGE

$14.90 - $22.50

52 WEEK CHANGE

-$8.58

MARKET CAP

198.362 M

YIELD

N/A

SHARES OUTSTANDING

10.786 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-28-2025

BETA

1.28

PUBLIC FLOAT

AVERAGE 10 VOLUME

$55,533

AVERAGE 30 VOLUME

$102,868

Company detail

CEO: Ofer Gonen
Region: US
Website: mediwound.com
Employees: 80
IPO year: 2014

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Medicinal Chemicals
Sector: Manufacturing

MediWound Ltd. markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.

MDWD - MediWound Ltd.